Fujirebio acquires Fluxus to accelerate new platform development based on ultra-high sensitivity detection technology
Fluxus is a Silicon Valley-based innovation company in the biotechnology area founded in 2016. The Fujirebio Group has been collaborating with Fluxus since 2017 in the development of a diagnostics platform based on ultra-high sensitivity detection technology. It is expected that this novel platform technology will create new clinical value through higher detection sensitivity diagnoses in areas such as Alzheimer's, cancer, and infectious diseases.
With this acquisition, the Fujirebio Group will accelerate the development of the next platform with Fluxus by incorporating its ultra-high sensitivity detection technology to complement and advance the functions of the LUMIPULSE fully automated chemiluminescent enzyme immunoassay system. In parallel, Fujirebio group aims to expand its lineup of clinically valuable reagents for the next platform. Through its Contract Development and Manufacturing Organization (CDMO) strategy, which is a key part of its global strategy, the Fujirebio Group aims to propose and supply core technologies related to ultra-high sensitivity detection, products based on the technologies, and reagents for the technologies to diagnostics companies around the world.
- Company name: Fluxus, Inc.
- Location: California, USA
- President & CEO: Peter Wagner
- Year of establishment: 2016
- Stock type: Unlisted
- Number of employees: Approximately 20
- Relationship with the Fujirebio Group: Co-development of a diagnostic platform using ultra-high sensitivity detection technology